secwatch.observer — SEC 8-K summary
======================================

Issuer:     ENANTA PHARMACEUTICALS INC (ENTA)
CIK:        0001177648
Form:       8-K
Filed at:   2022-02-08T23:59:59+00:00
Accession:  0000950170-22-000875
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Enanta Q1 net loss $30.1M; plans to start EDP-235 Phase 1 this month
--------------------------------------------------------------------

- Net loss of $30.1M ($1.48 per diluted share) vs $8.3M loss in prior-year quarter.
- Royalty revenue from MAVYRET/MAVIRET was $27.6M, down from $31.7M YoY.
- R&D expenses rose to $48.5M from $36.7M due to manufacturing for virology programs.
- Cash and marketable securities $347.7M; expects sufficient runway for at least two years.
- EDP-235 (oral COVID-19 treatment) Phase 1 dosing begins Feb 2022; RSVP topline data expected Q2 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1177648/000095017022000875/0000950170-22-000875-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1177648/000095017022000875/enta-20220208.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-000875

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer